Xtx Topco LTD Allogene Therapeutics, Inc. Transaction History

Xtx Topco LTD

$1.72 Billion
Q3 2025

A detailed history of Xtx Topco LTD transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Xtx Topco LTD holds 774,203 shares of ALLO stock, worth $952,269. This represents 0.06% of its overall portfolio holdings.

Number of Shares

774,203

Previous 27,772 2687.71%

Holding current value

$952,269

Previous $31,000 2996.77%

% of portfolio

0.06%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$1.03 - $1.66 $768,823 - $1.24 Million	746,431 Added 2687.71%	774,203 $960,000
Q2 2025 Aug 12, 2025	BUY	$0.95 - $1.7 $6,674 - $11,944	7,026 Added 33.87%	27,772 $31,000
Q1 2025 May 07, 2025	SELL	$1.4 - $2.84 $192,907 - $391,326	-137,791 Reduced 86.91%	20,746 $30,000
Q4 2024 Feb 13, 2025	BUY	$1.84 - $3.22 $291,708 - $510,489	158,537 New	158,537 $337,000
Q1 2024 May 13, 2024	BUY	$2.92 - $5.63 $1,106 - $2,133	379 Added 1.07%	35,765 $159,000

Q4 2023 Feb 13, 2024	SELL	$2.28 - $3.5 $88,017 - $135,114	-38,604 Reduced 52.17%	35,386 $113,000
Q3 2023 Nov 13, 2023	BUY	$3.17 - $5.96 $89,264 - $167,827	28,159 Added 61.44%	73,990 $234,000
Q2 2023 Aug 14, 2023	BUY	$4.53 - $6.74 $1,173 - $1,745	259 Added 0.57%	45,831 $227,000
Q1 2023 May 12, 2023	SELL	$4.92 - $8.21 $350,618 - $585,077	-71,264 Reduced 60.99%	45,572 $225,000
Q4 2022 Feb 14, 2023	BUY	$5.62 - $11.11 $439,450 - $868,735	78,194 Added 202.35%	116,836 $734,000
Q3 2022 Nov 14, 2022	BUY	$10.32 - $17.28 $398,785 - $667,733	38,642 New	38,642 $417,000

Others Institutions Holding ALLO

# of Institutions

182

Shares Held

138M

Call Options Held

76.6K

Put Options Held

36.2K

View Full List

About Allogene Therapeutics, Inc.

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $177M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

More about ALLO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.

Account